Patients with CLL may have both disease-associated and systemic treatment-associated immune dysfunction, leaving them vulnerable to infection.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.
Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.
Preclinical models indicated that dual inhibition of BTK and BCL2 may be synergistic.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Lenalidomide: Feasible for Patients With Relapsed, Refractory MCL
- Bloodroot and Cancer
- Perioperative Gabapentin May Improve Pain Management in Head and Neck Cancer
- ACA Decreased Non-Insurance Rates Among Patients With Head and Neck Cancer
- Acetaminophen May Decrease Opioid Use After Head and Neck Cancer Surgery